Current News Releases
Current News Releases
Six startups selected for tech-based accelerator program
For the second year, The Johns Hopkins University and Johns Hopkins Medicine are co-sponsoring an opportunity that prepares health information technology startups to present their innovative ideas to the world.
Conflicting scores from respected national rating systems may confuse rather than guide consumers’ choices about where to seek quality care, say experts from the Johns Hopkins Armstrong Institute for Patient Safety and Quality.
Mouse studies may lead to development of human therapies
Researchers at the Johns Hopkins University School of Medicine have now uncovered how a bacterial molecule controls the body’s response to TB infection and suggest that adjusting the level of this of this molecule may be a new way to treat the disease. The report appears this week as an advance online publication of Nature Medicine.
New formula gauges 10-year risk of dying
Analyzing data from 58,000 heart stress tests, Johns Hopkins cardiologists report they have developed a formula that estimates one’s risk of dying over a decade based on a person’s ability to exercise on a treadmill at an increasing speed and incline.
Findings are contrary to previous reports
Contrary to previous reports, a study led by Johns Hopkins researchers found that patients’ satisfaction scores only modestly improved based on the newly remodeled design of a hospital.
Competition among doctors’ offices, urgent care centers and retail medical clinics in wealthy areas of the U.S. often leads to an increase in the number of antibiotic prescriptions written per person, a team led by Johns Hopkins researchers has found.
Findings suggest high levels of false caregiver smoking reports, or second-hand exposure in multi-unit housing
Public health experts have long known that tobacco smoke exposure (TSE) can be harmful for children with bronchopulmonary dysplasia, a lung disease that often accompanies premature birth.
Laboratory studies suggest anticancer drug already in clinical trials in children may interrupt this gene pathway.
Working with cells taken from children with a very rare but ferocious form of brain cancer, Johns Hopkins Kimmel Cancer Center scientists have identified a genetic pathway that acts as a master regulator of thousands of other genes and may spur cancer cell growth and resistance to anticancer treatment.
First time there is data comparing effectiveness and safety of these drugs; Eylea found to outperform other drugs when vision loss is moderate to severe
A researcher from Johns Hopkins Medicine helped lead colleagues from across the country in a government-sponsored study by the Diabetic Retinopathy Clinical Research Network to discover that three drugs ? Eylea, Avastin and Lucentis ? used to treat diabetic macular edema are all effective. They also discovered that Eylea outperformed the other two drugs when vision loss was moderate to severe.
Group dynamics, not star proteins, drive mechanics of crucial cell process
Like a surgeon separating conjoined twins, cells have to be careful to get everything just right when they divide in two. Otherwise, the resulting daughter cells could be hobbled, particularly if they end up with too many or two few chromosomes. Successful cell division hangs on the formation of a dip called a cleavage furrow, a process that has remained mysterious. Now, researchers at Johns Hopkins have found that no single molecular architect directs the cleavage furrow’s formation; rather, it is a robust structure made of a suite of team players.
Four Web-based training modules developed by Johns Hopkins Medicine for emergency department personnel who treat patients with infectious diseases are now available on the Centers for Disease Control and Prevention (CDC)'s website.
What is happening in the brain of an actor reciting Hamlet’s “to be or not to be” soliloquy or of the person next to you at lunch saying, “Please pass the salt”? For 150 years, scientists have known that a brain region called Broca’s area plays a key role in speech production, but exactly what it does and how it does it have been a mystery.
Most “risk calculators” used by clinicians to gauge a patient’s chances of suffering a heart attack and guide treatment decisions appear to significantly overestimate the likelihood of a heart attack, according to results of a study by investigators at Johns Hopkins and other institutions.
Mechanical stress is a key driver of cell-cell fusion, study finds
Just as human relationships are a two-way street, fusion between cells requires two active partners: one to send protrusions into its neighbor, and one to hold its ground and help complete the process. Researchers have now found that one way the receiving cell plays its role is by having a key structural protein come running in response to pressure on the cell membrane, rather than waiting for chemical signals to tell it that it’s needed. The study, which helps open the curtain on a process relevant to muscle formation and regeneration, fertilization, and immune response, appears in the March 9 issue of the journal Developmental Cell.
Venom’s toxins will be a powerful tool for studying epilepsy, schizophrenia and chronic pain
For more than a decade, a vial of rare snake venom refused to give up its secret formula for lethality; its toxins had no effect on the proteins that most venoms target. Finally, an international team of researchers figured out its recipe: a toxin that permanently activates a crucial type of nerve cell protein, preventing the cells from resetting and causing deadly seizures in prey.
Both disorders involve faults in the same protein
Applying lessons learned from autism to brain cancer, researchers have discovered why elevated levels of the protein NHE9 add to the lethality of the most common and aggressive form of brain cancer, glioblastoma. Their discovery suggests that drugs designed to target NHE9 could help to successfully fight the deadly disease.
Henry Brem, M.D., director of the Department of Neurosurgery at Johns Hopkins, has been selected to receive a Castle Connolly National Physician of the Year Award for Clinical Excellence.
A new study by Johns Hopkins researchers links a well-known cell communication pathway called Notch to one of the most common — but overall still rare — brain tumors found in children.
Despite improvements in the past few decades with surgery, chemotherapy and radiation therapy, a predictably curative treatment for glioma does not yet exist. New insights into specific gene mutations that arise in this often deadly form of brain cancer have pointed to the potential of gene therapy, but it’s very difficult to effectively deliver toxic or missing genes to cancer cells in the brain. Now, Johns Hopkins researchers report they have used nanoparticles to successfully deliver a new therapy to glioma cells in the brains of rats, prolonging their lives.